S&P 500   4,283.85 (+0.24%)
DOW   33,573.28 (+0.03%)
QQQ   354.84 (-0.02%)
AAPL   179.21 (-0.21%)
MSFT   333.68 (-0.67%)
META   271.12 (-0.10%)
GOOGL   127.31 (+1.03%)
AMZN   126.61 (+1.05%)
TSLA   221.31 (+1.70%)
NVDA   386.54 (-1.32%)
NIO   7.87 (+2.61%)
BABA   86.69 (+2.71%)
AMD   124.23 (+5.34%)
T   15.66 (+1.75%)
F   12.93 (+2.70%)
MU   67.54 (-0.34%)
CGC   0.74 (-5.13%)
GE   105.46 (+1.31%)
DIS   92.16 (+1.27%)
AMC   4.64 (+0.22%)
PFE   38.37 (-0.72%)
PYPL   65.02 (+0.79%)
NFLX   399.29 (-1.05%)
S&P 500   4,283.85 (+0.24%)
DOW   33,573.28 (+0.03%)
QQQ   354.84 (-0.02%)
AAPL   179.21 (-0.21%)
MSFT   333.68 (-0.67%)
META   271.12 (-0.10%)
GOOGL   127.31 (+1.03%)
AMZN   126.61 (+1.05%)
TSLA   221.31 (+1.70%)
NVDA   386.54 (-1.32%)
NIO   7.87 (+2.61%)
BABA   86.69 (+2.71%)
AMD   124.23 (+5.34%)
T   15.66 (+1.75%)
F   12.93 (+2.70%)
MU   67.54 (-0.34%)
CGC   0.74 (-5.13%)
GE   105.46 (+1.31%)
DIS   92.16 (+1.27%)
AMC   4.64 (+0.22%)
PFE   38.37 (-0.72%)
PYPL   65.02 (+0.79%)
NFLX   399.29 (-1.05%)
S&P 500   4,283.85 (+0.24%)
DOW   33,573.28 (+0.03%)
QQQ   354.84 (-0.02%)
AAPL   179.21 (-0.21%)
MSFT   333.68 (-0.67%)
META   271.12 (-0.10%)
GOOGL   127.31 (+1.03%)
AMZN   126.61 (+1.05%)
TSLA   221.31 (+1.70%)
NVDA   386.54 (-1.32%)
NIO   7.87 (+2.61%)
BABA   86.69 (+2.71%)
AMD   124.23 (+5.34%)
T   15.66 (+1.75%)
F   12.93 (+2.70%)
MU   67.54 (-0.34%)
CGC   0.74 (-5.13%)
GE   105.46 (+1.31%)
DIS   92.16 (+1.27%)
AMC   4.64 (+0.22%)
PFE   38.37 (-0.72%)
PYPL   65.02 (+0.79%)
NFLX   399.29 (-1.05%)
S&P 500   4,283.85 (+0.24%)
DOW   33,573.28 (+0.03%)
QQQ   354.84 (-0.02%)
AAPL   179.21 (-0.21%)
MSFT   333.68 (-0.67%)
META   271.12 (-0.10%)
GOOGL   127.31 (+1.03%)
AMZN   126.61 (+1.05%)
TSLA   221.31 (+1.70%)
NVDA   386.54 (-1.32%)
NIO   7.87 (+2.61%)
BABA   86.69 (+2.71%)
AMD   124.23 (+5.34%)
T   15.66 (+1.75%)
F   12.93 (+2.70%)
MU   67.54 (-0.34%)
CGC   0.74 (-5.13%)
GE   105.46 (+1.31%)
DIS   92.16 (+1.27%)
AMC   4.64 (+0.22%)
PFE   38.37 (-0.72%)
PYPL   65.02 (+0.79%)
NFLX   399.29 (-1.05%)
NASDAQ:IART

Integra LifeSciences (IART) Stock Forecast, Price & News

$40.67
+1.03 (+2.60%)
(As of 06/6/2023 ET)
Compare
Today's Range
$39.68
$40.84
50-Day Range
$37.95
$58.98
52-Week Range
$37.36
$61.66
Volume
935,266 shs
Average Volume
593,792 shs
Market Capitalization
$3.33 billion
P/E Ratio
19.74
Dividend Yield
N/A
Price Target
$49.71

Integra LifeSciences MarketRank™ Forecast

Analyst Rating
Hold
1.83 Rating Score
Upside/​Downside
22.2% Upside
$49.71 Price Target
Short Interest
Healthy
4.13% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.50
Upright™ Environmental Score
News Sentiment
0.41mentions of Integra LifeSciences in the last 14 days
Based on 9 Articles This Week
Insider Trading
Acquiring Shares
$299,992 Bought Last Quarter
Proj. Earnings Growth
12.38%
From $3.23 to $3.63 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.45 out of 5 stars

Medical Sector

153rd out of 981 stocks

Surgical & Medical Instruments Industry

16th out of 97 stocks


IART stock logo

About Integra LifeSciences (NASDAQ:IART) Stock

Integra LifeSciences Holdings Corp. engages in the provision of regenerative tissue technologies and neurological solutions dedicated to limiting uncertainty for clinicians. It operates under the Codman Specialty Surgical (CSS) and Tissue Technologies (TT) segments. The CSS segment includes technologies and instrumentation used for neurosurgery, neurocritical care, and otolaryngology. The TT segment focuses on complex wound surgery, surgical reconstruction, and peripheral nerve repair. The company was founded by Richard E. Caruso in 1989 and is headquartered in Princeton, NJ.

Receive IART Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Integra LifeSciences and its competitors with MarketBeat's FREE daily newsletter.

IART Stock News Headlines

Wall Street Legend Who Called AMZN Crash Issues New Sell Alert
Now, after years of big gains, he says one popular company's day in the sun is finally coming to an end. You must get off this sinking ship – NOW. 1 million people follow him for his surprisingly accurate predictions. His new sell alert could save your wealth in 2023.
Integra Investor Alert
Integra LifeSciences (NASDAQ: IART)
[BREAKING] New "Living Missile" to Replace Nuclear Missiles
CBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!
Integra Shareholder Notice
Why Integra LifeSciences Stock Is Crashing Today
Integra LifeSciences tumbles after product recall
Why Integra LifeSciences Stock Is Tumbling
See More Headlines

IART Price History

IART Company Calendar

Last Earnings
4/26/2023
Today
6/06/2023
Next Earnings (Estimated)
7/26/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
Health Care Equipment
Sector
Medical
Current Symbol
NASDAQ:IART
CUSIP
45798520
Employees
3,722
Year Founded
1989

Price Target and Rating

Average Stock Price Forecast
$49.71
High Stock Price Forecast
$65.00
Low Stock Price Forecast
$39.00
Forecasted Upside/Downside
+22.8%
Consensus Rating
Hold
Rating Score (0-4)
1.83
Research Coverage
6 Analysts

Profitability

Net Income
$180.55 million
Pretax Margin
13.08%

Debt

Sales & Book Value

Annual Sales
$1.56 billion
Cash Flow
$5.05 per share
Book Value
$21.57 per share

Miscellaneous

Free Float
79,529,000
Market Cap
$3.32 billion
Optionable
Optionable
Beta
1.16

Social Links


Key Executives

  • Jan D. de Witte
    President, Chief Executive Officer & Director
  • Steve Leonard
    Vice President-Global Operations & Supply Chain
  • Jeffrey Alan MosebrookJeffrey Alan Mosebrook
    Senior Vice President-Finance & PAO
  • William Compton
    Chief Information Officer & Senior Vice President
  • Stuart Hart
    Chief Medical Officer & Vice President













IART Stock - Frequently Asked Questions

Should I buy or sell Integra LifeSciences stock right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Integra LifeSciences in the last twelve months. There are currently 2 sell ratings, 3 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" IART shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in IART, but not buy additional shares or sell existing shares.
View IART analyst ratings
or view top-rated stocks.

What is Integra LifeSciences' stock price forecast for 2023?

6 Wall Street research analysts have issued twelve-month price objectives for Integra LifeSciences' shares. Their IART share price forecasts range from $39.00 to $65.00. On average, they predict the company's share price to reach $49.71 in the next year. This suggests a possible upside of 22.8% from the stock's current price.
View analysts price targets for IART
or view top-rated stocks among Wall Street analysts.

How have IART shares performed in 2023?

Integra LifeSciences' stock was trading at $56.07 at the start of the year. Since then, IART shares have decreased by 27.8% and is now trading at $40.50.
View the best growth stocks for 2023 here
.

Are investors shorting Integra LifeSciences?

Integra LifeSciences saw a decrease in short interest in the month of May. As of May 15th, there was short interest totaling 2,930,000 shares, a decrease of 20.6% from the April 30th total of 3,690,000 shares. Based on an average trading volume of 621,300 shares, the short-interest ratio is currently 4.7 days. Approximately 4.1% of the shares of the company are sold short.
View Integra LifeSciences' Short Interest
.

When is Integra LifeSciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, July 26th 2023.
View our IART earnings forecast
.

How were Integra LifeSciences' earnings last quarter?

Integra LifeSciences Holdings Co. (NASDAQ:IART) announced its quarterly earnings results on Wednesday, April, 26th. The life sciences company reported $0.74 earnings per share for the quarter, meeting analysts' consensus estimates of $0.74. The life sciences company had revenue of $380.85 million for the quarter, compared to the consensus estimate of $373.21 million. Integra LifeSciences had a trailing twelve-month return on equity of 16.29% and a net margin of 11.00%. The business's revenue was up 1.1% on a year-over-year basis. During the same quarter last year, the firm posted $0.74 EPS.

When did Integra LifeSciences' stock split?

Shares of Integra LifeSciences split before market open on Tuesday, January 3rd 2017. The 2-1 split was announced on Thursday, December 22nd 2016. The newly created shares were distributed to shareholders after the closing bell on Wednesday, December 21st 2016. An investor that had 100 shares of stock prior to the split would have 200 shares after the split.

What guidance has Integra LifeSciences issued on next quarter's earnings?

Integra LifeSciences updated its second quarter 2023 earnings guidance on Thursday, April, 27th. The company provided earnings per share guidance of $0.75-$0.79 for the period, compared to the consensus estimate of $0.85. The company issued revenue guidance of $396.00 million-$400.00 million, compared to the consensus revenue estimate of $404.78 million.

What is Peter J. Arduini's approval rating as Integra LifeSciences' CEO?

173 employees have rated Integra LifeSciences Chief Executive Officer Peter J. Arduini on Glassdoor.com. Peter J. Arduini has an approval rating of 74% among the company's employees.

What other stocks do shareholders of Integra LifeSciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Integra LifeSciences investors own include Boeing (BA), NVIDIA (NVDA), AbbVie (ABBV), Adobe (ADBE), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Intel (INTC), Marvell Technology (MRVL), Alexion Pharmaceuticals (ALXN) and Abbott Laboratories (ABT).

What is Integra LifeSciences' stock symbol?

Integra LifeSciences trades on the NASDAQ under the ticker symbol "IART."

Who are Integra LifeSciences' major shareholders?

Integra LifeSciences' stock is owned by a variety of retail and institutional investors. Top institutional investors include Champlain Investment Partners LLC (6.31%), Clearbridge Investments LLC (3.35%), Cooke & Bieler LP (3.25%), Dimensional Fund Advisors LP (1.58%), Victory Capital Management Inc. (1.50%) and Geode Capital Management LLC (1.34%). Insiders that own company stock include Eric Schwartz, Glenn Coleman, Jeffrey Mosebrook, Lisa Evoli, Michael J Mcbreen, Raymond G Murphy, Richard E Caruso, Stuart Essig, Tru St Partnership, LP and Witte Jan De.
View institutional ownership trends
.

How do I buy shares of Integra LifeSciences?

Shares of IART stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Integra LifeSciences' stock price today?

One share of IART stock can currently be purchased for approximately $40.50.

How much money does Integra LifeSciences make?

Integra LifeSciences (NASDAQ:IART) has a market capitalization of $3.32 billion and generates $1.56 billion in revenue each year. The life sciences company earns $180.55 million in net income (profit) each year or $2.06 on an earnings per share basis.

How many employees does Integra LifeSciences have?

The company employs 3,722 workers across the globe.

Does Integra LifeSciences have any subsidiaries?
The following companies are subsidiares of Integra LifeSciences: ACell Inc, ACell Inc., Arkis BioSciences, Arkis Biosciences Inc., Ascension Orthopedics Inc., Ascension Orthopedics Limited, BIMECO Inc., BioD LLC, BioDlogics LLC, BioRecovery LLC, CardioDyne Inc., Cathtec Incorporated, Caveangle Limited, Codman Neuro, Confluent Surgical, Confluent Surgical Inc., Derma First Aid Products Inc., Derma Sciences, Derma Sciences Canada Inc., Derma Sciences Europe Limited, Derma Sciences Inc., EndoSolutions Inc., Fiber Imaging Technologies Inc., GMS Gesellschaft für medizinische Sondentechnik mbH, ILS Financing (Ireland) Limited, ILS Financing Corporation, ILS Services Switzerland Ltd., ILS Surgical Investments LLC, INS Sweden AB, Integra Burlington MA Inc., Integra CI Inc., Integra Canada ULC, Integra Euro Holdings Inc., Integra France Holdings SAS, Integra German Holdings GmbH, Integra GmbH, Integra Japan K.K., Integra LS (Benelux) NV, Integra LS Mexico S. DE R. L. DE C.V., Integra LifeSciences (Canada) Holdings Inc., Integra LifeSciences (Ireland) Limited, Integra LifeSciences (Shanghai) Co. Ltd., Integra LifeSciences Austria GmbH, Integra LifeSciences Brazil Ltda., Integra LifeSciences Corporation, Integra LifeSciences Enterprises LLLP, Integra LifeSciences Financing (Cyprus) Limited, Integra LifeSciences Italy S.r.l., Integra LifeSciences Middle East FZ-LLC, Integra LifeSciences Production Corporation, Integra LifeSciences Sales LLC, Integra LifeSciences Services (France) SAS, Integra LifeSciences Shared Services (Ireland) Limited, Integra LifeSciences Singapore Pte. Ltd., Integra LifeSciences Spain S.L., Integra LifeSciences Switzerland Sárl, Integra Luxtec Inc., Integra ME GmbH, Integra MicroFrance SAS, Integra NeuroSciences (International) Inc., Integra NeuroSciences Holdings (UK) Limited, Integra NeuroSciences Holdings B.V., Integra NeuroSciences Implants (France) SAS, Integra NeuroSciences Limited, Integra Neurosciences, Integra Neurosciences Pty Ltd. (AUS), Integra Neurosciences Pty Ltd. (NZ), Integra Receivables LLC, Integra Sales Inc., Integra Selector LLC, Integra Switzerland Holdings Sarl, Integra York PA Inc., IsoTis NV, IsoTis T.E. Facility B.V., J. Jamner Surgical Instruments Inc., Jarit GmbH, Kinetikos Medical, Koby Ventures II L.P. dba Metasurg, LXU Healthcare Inc. - Medical Specialty Products, MedEfficiency Inc., Medtronic Xomed Instrumentation SAS, Miltex, Minnesota Scientific Inc., Nantong Derma Medical Products Co. Ltd., Newdeal Inc., Newdeal SAS, Omni-Tract, Precise Dental Holding Corp., Precise Dental Internacional S.A. de C.V., Precise Dental Products Ltd., Precision Dental International Inc., Rebound Therapeutics, Rebound Therapeutics Corporation, Spembly Cryosurgery Limited, Spembly Medical Limited, TEI Biosciences (UK) Limited, TEI Biosciences Inc., TEI Biosciences Inc., TEI Medical Inc., TGX Medical Systems, TGX Medical Systems LLC, Tarsus Medical Inc., Tarsus Medical Inc., Tekmed Instruments S.p.A, Theken Disc, Theken Spine, and Therics.
Read More
How can I contact Integra LifeSciences?

Integra LifeSciences' mailing address is 311 ENTERPRISE DRIVE, PLAINSBORO NJ, 08536. The official website for the company is www.integralife.com. The life sciences company can be reached via phone at (609) 275-0500, via email at ir@integralife.com, or via fax at 609-750-4277.

This page (NASDAQ:IART) was last updated on 6/6/2023 by MarketBeat.com Staff

My Account -